Molecular Forecaster and Oxeltis Forge Strategic Collaboration to Enhance Client’s Drug Design and Synthesis
MONTREAL, CANADA, and MONTPELLIER, FRANCE, May 12, 2025 – Molecular Forecaster Inc. (MFI) and Oxeltis S.A. (Oxeltis) are excited to announce a strategic partnership leveraging the strengths of both organizations to offer seamless integration of in silico design with high-quality chemical synthesis.
Both MFI and Oxeltis focus on accelerating the preclinical stages of the drug design process. MFI is a research-as-a-service (RaaS) organization combining human expertise and proprietary technology that integrates chemistry and computational modeling to reduce design cycles in small molecule campaigns. Oxeltis contracts services in medicinal and fine organic chemistry for life science research, including hit to pre-clinical candidate optimization, custom synthesis and early scale-up route scouting.
“At MFI, we believe the primary benefit of computational drug design is to help humans learn faster so they can make smarter, more strategic decisions that save time, money, and lives,” says Josh Pottel, MFI’s CEO. “We also believe collaboration is key to achieving the greatest possible results. Forming complementary relationships, like this one with Oxeltis, aligns with our values and the way we do business, and we are excited to see where we’ll go together.”
Under the collaboration, MFI and Oxeltis will help organizations prioritize candidates, reduce design cycles, and boost productivity by integrating MFI’s predictive modeling and customized, collaborative CADD solutions with Oxeltis’ wet lab-based medicinal chemistry design and synthesis. The strategic partnership further benefits clients by streamlining project management and administration between the organizations, without sacrificing the individual expertise of either.
“This collaboration is an opportunity to outsource critical research activities to companies with highly specialized and complementary research expertise, and a proven and productive working relationship,” says Jean-Marc Allaire, CEO of Oxeltis. “Whether organizations need virtual screening campaigns, synthesis of focused libraries, or fully integrated support for early discovery programs, our combined knowledge and approaches enable us to customize innovative and efficient solutions for clients that set them up for the greatest success.”
To learn more about how the MFI-Oxeltis partnership can support early-stage drug-design projects, the Oxeltis team will be attending the ACSMEDI-EFMC Medicinal Chemistry Frontiers event in Chicago, May 12 – 15, 2025, and both teams will be present at BIO in Boston, June 16-19. You can schedule a discussion at contact@oxeltis.com or by emailing the team at MFI at info@molecularforecaster.com.
-//-
ABOUT MFI
Molecular Forecaster Inc. (MFI) helps organizations make smarter decisions in drug design. We’ve spent six years democratizing computer-aided drug design via our highly collaborative research-as-a-service model. Today, we’re integrating what we’ve learned into new and improved software tools. Our goal? To become the go-to partner in small molecule drug design, combining proprietary tools and technology, our expertise and know-how, and our all-in approach to collaboration that sets our partners up for success.
ABOUT OXELTIS
Oxeltis is a Contract Research Organization (CRO) specializing in Medicinal and Fine Organic Chemistry, with over 15 years of experience in highly functionalized organic compounds. Our team of chemists focuses on several core technology platforms: Heterocycles, Nucleos(t)ides, Phosphoramidites, Peptides, Oligosaccharides, Linkers, PROTACs, and route scouting, with synthesis capacities ranging from mg to 100g. Over the past decade, Oxeltis has been a trusted partner in drug discovery programs for international companies and institutes, including five of the top 10 pharmaceutical groups, as well as innovative biotechs from Europe, Israel, North America, and Japan. Our commitment to excellence and reliability (ISO 9001 accreditation) has earned us a reputation for delivering high-quality results that drive scientific progress.